Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Regulatory
  • VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain
  • Regulatory

VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain

Pharmaceutical Technology

VERTANICAL has received breakthrough therapy designation from the US FDA for VER-01, its investigational non-opioid treatment for chronic low back pain.

Pain & Anaesthesia

Read full story

pharminent May 19, 2026 (Last updated: May 21, 2026)

Pharmaceutical Technology

VERTANICAL has received breakthrough therapy designation from the US FDA for VER-01, its investigational non-opioid treatment for chronic low back pain.

Pain & Anaesthesia

Read full story

Post navigation

Previous: Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
Next: Sanofi says drug for rare disease AATD tops standard care

Related Stories

  • Regulatory

Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion

pharminent September 10, 2026
  • Regulatory

HHS appoints permanent FDA CBER, CDER heads

pharminent September 10, 2026
  • Regulatory

FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer

pharminent September 7, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.